Analysis of the mechanisms of development of neurorheumatological consequences of COVID-19 and the possibility of their pharmacological correction

We present the review of clinical and experimental studies on pathogenesis neurorheumatological complications (NRC) in COVID-19. The influence systemic hyperinflammation caused by impaired innate immunity functioning neurovascular endothelium bloodbrain barrier, activation signaling pathways parainfectious autoimmunity central nervous system were analyzed. Hyperinflammation has been shown to contribute development NRC potential therapeutic efficacy drugs, including those based chondroitin sulfate, which can be used for prevention treatment COVID-19, is considered.